These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28222460)

  • 1. Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Overview of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus.
    Miller EM
    J Fam Pract; 2017 Feb; 66(2 Suppl):S5-S12. PubMed ID: 28222460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Role of the Kidney in Glucose Homeostasis: Implications for SGLT-2 Inhibition in the Treatment of Type 2 Diabetes Mellitus.
    Miller EM
    J Fam Pract; 2017 Feb; 66(2 Suppl):S3-S5. PubMed ID: 28222459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Individualizing Treatment With SGLT-2 Inhibitor Therapy in Type 2 Diabetes Mellitus.
    Miller EM
    J Fam Pract; 2017 Feb; 66(2 Suppl):S13-S16. PubMed ID: 28222461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects and safety of SGLT-2 inhibitors.
    Halimi S; Vergès B
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?
    Swislocki AL; Jialal I
    Metab Syndr Relat Disord; 2016 Feb; 14(1):3-6. PubMed ID: 26677930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Rajasekeran H; Cherney DZ; Lovshin JA
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure.
    Riggs K; Ali H; Taegtmeyer H; Gutierrez AD
    Metab Syndr Relat Disord; 2015 Sep; 13(7):292-7. PubMed ID: 26125313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
    Imprialos KP; Sarafidis PA; Karagiannis AI
    J Hypertens; 2015 Nov; 33(11):2185-97. PubMed ID: 26372321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.
    Lioudaki E; Whyte M; Androulakis ES; Stylianou KG; Daphnis EK; Ganotakis ES
    Clin Pharmacol Ther; 2017 Sep; 102(3):470-480. PubMed ID: 28480956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 inhibition in patients with kidney disease.
    Gilbert RE
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S23-7. PubMed ID: 25554068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
    Abdul-Ghani MA; Norton L; Defronzo RA
    Endocr Rev; 2011 Aug; 32(4):515-31. PubMed ID: 21606218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
    Thomas MC; Jandeleit-Dahm K; Bonnet F
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
    DeFronzo RA; Davidson JA; Del Prato S
    Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.